Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
IMCL's Cash to Debt is ranked higher than
98% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: 34.92 vs. IMCL: No Debt )
IMCL' s 10-Year Cash to Debt Range
Min: 9999   Max: No Debt
Current: No Debt

Equity to Asset 0.86
IMCL's Equity to Asset is ranked higher than
87% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. IMCL: 0.86 )
IMCL' s 10-Year Equity to Asset Range
Min: 0.86   Max: 0.86
Current: 0.86

Interest Coverage No Debt
IMCL's Interest Coverage is ranked higher than
86% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IMCL: No Debt )
IMCL' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 28.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -413720.00
IMCL's Operating margin (%) is ranked lower than
54% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. IMCL: -413720.00 )
IMCL' s 10-Year Operating margin (%) Range
Min: -78.69   Max: -78.69
Current: -413720

Net-margin (%) -408960.00
IMCL's Net-margin (%) is ranked lower than
54% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. IMCL: -408960.00 )
IMCL' s 10-Year Net-margin (%) Range
Min: -37.16   Max: -37.16
Current: -408960

ROE (%) -135.55
IMCL's ROE (%) is ranked higher than
53% of the 1339 Companies
in the Global Biotechnology industry.

( Industry Median: -30.19 vs. IMCL: -135.55 )
IMCL' s 10-Year ROE (%) Range
Min: -129.77   Max: -129.77
Current: -135.55

ROA (%) -124.67
IMCL's ROA (%) is ranked higher than
51% of the 1463 Companies
in the Global Biotechnology industry.

( Industry Median: -24.77 vs. IMCL: -124.67 )
IMCL' s 10-Year ROA (%) Range
Min: -122.21   Max: -63.26
Current: -124.67

-122.21
-63.26
ROC (Joel Greenblatt) (%) -20852.82
IMCL's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 1426 Companies
in the Global Biotechnology industry.

( Industry Median: -347.18 vs. IMCL: -20852.82 )
IMCL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -370914.29   Max: -28800
Current: -20852.82

-370914.29
-28800
» IMCL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IMCL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.00
IMCL's P/B is ranked higher than
53% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 6.95 vs. IMCL: 9.00 )
IMCL' s 10-Year P/B Range
Min: 0   Max: 9.2
Current: 9

0
9.2
P/S 28890.00
IMCL's P/S is ranked lower than
85% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 37.39 vs. IMCL: 28890.00 )
IMCL' s 10-Year P/S Range
Min: 0   Max: 29415.3
Current: 28890

0
29415.3
EV-to-EBIT -7.66
IMCL's EV-to-EBIT is ranked higher than
76% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. IMCL: -7.66 )
IMCL' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -7.66

Current Ratio 0.09
IMCL's Current Ratio is ranked lower than
54% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. IMCL: 0.09 )
IMCL' s 10-Year Current Ratio Range
Min: 0.04   Max: 9.1
Current: 0.09

0.04
9.1
Quick Ratio 0.09
IMCL's Quick Ratio is ranked lower than
54% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. IMCL: 0.09 )
IMCL' s 10-Year Quick Ratio Range
Min: 0.04   Max: 9.1
Current: 0.09

0.04
9.1
Days Sales Outstanding 4.00
IMCL's Days Sales Outstanding is ranked higher than
98% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. IMCL: 4.00 )
IMCL' s 10-Year Days Sales Outstanding Range
Min: 67.81   Max: 67.81
Current: 4

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -13.10
IMCL's Earnings Yield (Greenblatt) is ranked higher than
50% of the 1417 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. IMCL: -13.10 )
IMCL' s 10-Year Earnings Yield (Greenblatt) Range
Min: -35.1   Max: 0
Current: -13.1

-35.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
» More Articles for IMCL

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
IMMUNOCLIN CORP Financials May 06 2015
Subsidiary of ImmunoClin Corporation (IMCL) receives controlled drug license in the United Kingdom Apr 02 2015
IMMUNOCLIN CORP Financials Mar 12 2015
Activist investor at Ariad Pharmaceuticals has long history of wins Mar 11 2015
ImmunoClin Corporation (IMCL) Relocates European Headquarters and Laboratories to London, UK Mar 10 2015
Activists want 'imminent retirement' of Ariad CEO Feb 20 2015
IMMUNOCLIN CORP Files SEC form 10-Q, Quarterly Report Dec 22 2014
Cannabis Science Announces Corporate Changes, Appointing Raymond Dabney As President And CEO And Dr.... Nov 06 2014
IMMUNOCLIN CORP Files SEC form 10-Q, Quarterly Report Sep 29 2014
Cannabis Science, Inc. (CBIS) Signs Drug Development and Laboratory Services Agreement with... Sep 29 2014
ImmunoClin Corporation (IMCL) Announces the Appointment of Infectious Disease Expert, Dr. Heinz... Aug 05 2014
IMMUNOCLIN CORP Files SEC form 8-K, Other Events Aug 01 2014
ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC Jul 29 2014
IMMUNOCLIN CORP Files SEC form 10-Q, Quarterly Report Jul 24 2014
IMMUNOCLIN CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial... Jul 08 2014
ImmunoClin Corporation (IMCL) Recruits Prof. Jean Mariani to the Company's Scientific Advisory Board Jun 05 2014
ImmunoClin Corporation (IMCL) Appoints Prof. Antony Bayer to the Company's Scientific Advisory Board May 27 2014
ImmunoClin Corporation (IMCL) Announces the Appointment of Computing Systems Specialist and... May 22 2014
ImmunoClin Corporation (IMCL) Proudly Announces the Appointment of Molecular Biologist and... Apr 30 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK